|
Index | - | P/E | - | EPS (ttm) | -0.71 | Insider Own | 0.80% | Shs Outstand | 12.09M | Perf Week | -16.67% |
Market Cap | 28.09M | Forward P/E | - | EPS next Y | -1.02 | Insider Trans | -20.81% | Shs Float | 11.81M | Perf Month | -9.09% |
Income | -7.40M | PEG | - | EPS next Q | -0.20 | Inst Own | 5.30% | Short Float | 5.19% | Perf Quarter | 41.94% |
Sales | 0.80M | P/S | 35.12 | EPS this Y | 63.60% | Inst Trans | -47.28% | Short Ratio | 0.28 | Perf Half Y | 45.70% |
Book/sh | 0.96 | P/B | 2.29 | EPS next Y | -44.30% | ROA | -54.30% | Target Price | - | Perf Year | -26.67% |
Cash/sh | 0.95 | P/C | 2.32 | EPS next 5Y | - | ROE | -59.30% | 52W Range | 1.18 - 3.73 | Perf YTD | -10.93% |
Dividend | - | P/FCF | - | EPS past 5Y | 36.60% | ROI | -67.80% | 52W High | -41.02% | Beta | 0.63 |
Dividend % | - | Quick Ratio | 10.00 | Sales past 5Y | -3.10% | Gross Margin | - | 52W Low | 86.44% | ATR | 0.24 |
Employees | 8 | Current Ratio | 10.00 | Sales Q/Q | 50.00% | Oper. Margin | - | RSI (14) | 38.43 | Volatility | 8.16% 10.87% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 28.80% | Profit Margin | - | Rel Volume | 0.12 | Prev Close | 2.32 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | Feb 10 AMC | Payout | - | Avg Volume | 2.17M | Price | 2.20 |
Recom | 2.00 | SMA20 | -14.15% | SMA50 | -10.64% | SMA200 | 19.98% | Volume | 274,815 | Change | -5.17% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite